Rna virus vectors carrying dai and ripk3

Abstract

RNA virus vectors comprising a gene encoding the DNA-dependent activator of interferon-regulatory factors (DAI) protein, and optionally further comprising a gene encoding the receptor-interacting serine; threonine-protein kinase 3 (RIPK3) may be used therapeutically to induce cell death, as well as an inflammatory immune response, against tumors and virally-infected cells.

1 - 11 . (canceled) 
     
     
         12 . A method for treating a tumor in a subject in need thereof, comprising infecting cells of the tumor with an RNA virus vector, wherein the RNA virus vector comprises an RNA virus comprising a gene encoding the human DNA-dependent activator of interferon-regulatory factors (DAI) protein and a gene encoding the human receptor-interacting serine/threonine-protein kinase 3 (RIPK3) protein. 
     
     
         13 . The method according to  claim 12 , wherein the tumor is a tumor of the head and neck, esophagus, lung, breast, pancreas, kidney, liver, stomach, colon, ovary, uterus, prostate gland, bladder, or blood. 
     
     
         14 . A method for treating a viral infection in a subject in need thereof, comprising infecting cells infected with the viral infection with an RNA virus vector, wherein the RNA virus vector comprises an RNA virus comprising a gene encoding the human DNA-dependent activator of interferon-regulatory factors (DAI) protein and a gene encoding the human receptor-interacting serine/threonine-protein kinase 3 (RIPK3) protein. 
     
     
         15 . The method according to  claim 14 , wherein the viral infection comprises a negative sense RNA virus infection. 
     
     
         16 . The method according to  claim 15 , wherein the negative sense RNA virus infection is an influenza virus infection. 
     
     
         17 . The method according to  claim 16 , wherein the influenza virus infection is an influenza type A virus infection, an influenza type B virus infection or an influenza type C virus infection. 
     
     
         18 . The method according to  claim 14 , wherein the subject is a human. 
     
     
         19 - 25 . (canceled) 
     
     
         26 . A method for treating a tumor in a subject in need thereof, comprising infecting cells of the tumor with an RNA virus vector, wherein the RNA virus vector comprises an RNA virus comprising a gene encoding the human DNA-dependent activator of interferon-regulatory factors (DAI) protein. 
     
     
         27 . The method according to  claim 26 , wherein the tumor is a tumor of the head and neck, esophagus, lung, breast, pancreas, kidney, liver, stomach, colon, ovary, uterus, prostate gland, bladder, or blood. 
     
     
         28 . A method for treating a viral infection in a subject in need thereof, comprising infecting cells infected with the viral infection with an RNA virus vector, wherein the RNA virus vector comprises an RNA virus comprising a gene encoding the human DNA-dependent activator of interferon-regulatory factors (DAI) protein. 
     
     
         29 . The method according to  claim 28 , wherein the viral infection comprises a negative sense RNA virus infection. 
     
     
         30 . The method according to  claim 29 , wherein the negative sense RNA virus infection is an influenza virus infection. 
     
     
         31 . The method according to  claim 30 , wherein the influenza virus infection is an influenza type A virus infection, an influenza type B virus infection, or an influenza type C virus infection. 
     
     
         32 . The method according to  claim 28 , wherein the subject is a human. 
     
     
         33 - 35 . (canceled) 
     
     
         36 . The method according to  claim 12 , wherein the subject is a human. 
     
     
         37 . The method according to  claim 26 , wherein the subject is a human. 
     
     
         38 . The method according to  claim 12 , wherein the RNA virus vector is actively targeted to the tumor. 
     
     
         39 . The method according to  claim 26 , wherein the RNA virus vector is actively targeted to the tumor. 
     
     
         40 . The method according to  claim 14 , wherein the RNA virus vector is actively targeted to the cells infected with the viral infection. 
     
     
         41 . The method according to  claim 28 , wherein the RNA virus vector is actively targeted to the cells infected with the viral infection.